SynthesisEuropean journal of pharmacology2021
Interferon therapy in patients with SARS, MERS, and COVID-19: A systematic review and meta-analysis of clinical studies.
Synthesis in European journal of pharmacology, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 15 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
15 citing papers in PubMed, 2 syntheses or guidelines pooled it, 36 citations in OpenAlex.
- Olfactory system measurements in COVID-19: a systematic review and meta-analysis.Neuroradiology · 2023Pooled it
- Pooled it
- Harnessing the power of IFN for therapeutic approaches to COVID-19.Journal of virology · 2024Review
- Mental Healthcare in Pediatrics During the COVID-19 Pandemic: A Call for International Public Health Action.Advances in experimental medicine and biology · 2024Review
- Reduced replication but increased interferon resistance of SARS-CoV-2 Omicron BA.1.Life science alliance · 2023Article
- Deep brain stimulation (DBS) as a therapeutic approach in gait disorders: What does it bring to the table?IBRO neuroscience reports · 2023Review
- Dominant CT Patterns and Immune Responses during the Early Infection Phases of Different SARS-CoV-2 Variants.Viruses · 2023Observational
- Interferons in COVID-19: missed opportunities to prove efficacy in clinical phase III trials?Frontiers in medicine · 2023Article
- Microglia dynamics in aging-related neurobehavioral and neuroinflammatory diseases.Journal of neuroinflammation · 2022Review
- Article
- Targeting transgenic proteins to alpha granules for platelet-directed gene therapy.Molecular therapy. Nucleic acids · 2022Article
- Integrative multiomics and in silico analysis revealed the role of ARHGEF1 and its screened antagonist in mild and severe COVID-19 patients.Journal of cellular biochemistry · 2022Article
- Medical imaging of pulmonary disease in SARS-CoV-2-exposed non-human primates.Trends in molecular medicine · 2022Review
- Interferon-based agents for current and future viral respiratory infections: A scoping literature review of human studies.PLOS global public health · 2022Article
- Serum soluble Fas ligand is a severity and mortality prognostic marker for COVID-19 patients.Frontiers in immunology · 2022Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Concern regarding coronavirus (CoV) outbreaks has stayed relevant to global health in the last decades. Emerging COVID-19 infection, caused by the novel SARS-CoV2, is now a pandemic, bringing a substantial burden to human health. Interferon (IFN), combined with other antivirals and various treatments, has been used to treat and prevent MERS-CoV, SARS-CoV, and SARS-CoV2 infections. We aimed to assess the clinical efficacy of IFN-based treatments and combinational therapy with antivirals, corticosteroids, traditional medicine, and other treatments. Major healthcare databases and grey literature were investigated. A three-stage screening was utilized, and included studies were checked against the protocol eligibility criteria. Risk of bias assessment and data extraction were performed, followed by narrative data synthesis. Fifty-five distinct studies of SARS-CoV2, MERS-CoV, and SARS-CoV were spotted. Our narrative synthesis showed a possible benefit in the use of IFN. A good quality cohort showed lower CRP levels in Arbidol (ARB) + IFN group vs. IFN only group. Another study reported a significantly shorter chest X-ray (CXR) resolution in IFN-Alfacon-1 + corticosteroid group compared with the corticosteroid only group in SARS-CoV patients. In a COVID-19 trial, total adverse drug events (ADEs) were much lower in the Favipiravir (FPV) + IFN-α group compared with the LPV/RTV arm (P = 0.001). Also, nausea in patients receiving FPV + IFN-α regimen was significantly lower (P = 0.03). Quantitative analysis of mortality did not show a conclusive effect for IFN/RBV treatment in six moderately heterogeneous MERS-CoV studies (log OR = -0.05, 95% CI: (-0.71,0.62), I
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.